Kymera Therapeutics (KYMR) stays a Strong Buy on KT-621 Phase 1b AD results, FDA Fast Track, and $1.6B cash runway—click to ...

There are devastating conditions that currently offer very few options for families. This is what science has planned.

Alignment with the FDA across proposed study parameters of RESTORE, a 16-week registrational study evaluating NVG-291 in chronic ...

NovaBridge Biosciences remains a high-risk, catalyst-driven biotech, trading near cash value with a focus on pipeline ...

In 2025, Seres received a non-dilutive award from CARB-X for up to $3.6 million, representing the Company’s second CARB-X award, to support development of an oral liquid formulation based on SER-155 ...

Pure Cycle Corporation (NASDAQ Capital Market: PCYO) ('Pure Cycle”, 'we”, 'us” or 'our”) announced its financial results for the three and six months ended February 28, 2026. Pure Cycle reported $1.1 ...

Pure Cycle Corporation (NASDAQ Capital Market: PCYO) ("Pure Cycle", "we", "us" or "our") announced its financial results for the three and six months ended ...

Net loss attributable to NovaBridge was $46.3 million for the year ended December 31, 2025, compared to $22.2 million for the year ended December 31, 2024. Net loss per share attributable to ordinary ...

ClearSign Technologies Corporation (NASDAQ:CLIR) Q4 2025 Earnings Call Transcript April 9, 2026 ClearSign Technologies Corporation beats earnings expectations. Reported EPS is $0.01, expectations were ...